DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2020 của Trillium Therapeutics Inc.

Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. They have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective “do not eat” signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this “do not eat … More ” signal with decoy receptors, they aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.

TÊN CÔNG TY / COMPANY
Trillium Therapeutics Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
TSX (Canada)

MÃ CHỨNG KHOÁN / TICKER
TRIL

KỲ BÁO CÁO
2020

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare